The Cross-Border Biotech Blog

MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for March 30th, 2015!   The past week saw Valeant close their offering of 7,286,432 shares, raising proceeds of about $1.45 billion. For details on this financing, as well as for the rest of the week’s stories, continue reading this week’s Monday Deal Review! Valeant Pharmaceuticals International, Inc (NYSE: […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for March 27th, 2015! Mucosal Immunol. 2015 Mar 18. doi: 10.1038/mi.2015.15. TGF-β-mediated airway tolerance to allergens induced by peptide-based immunomodulatory mucosal vaccination.   Stem Cells. 2015 Mar 12. doi: 10.1002/stem.1994. Cellular reprogramming allows generation of autologous hematopoietic progenitors from AML patients that are devoid of patient-specific genomic aberrations.   Neuron. 2015 […]

read more


Part5_Biotech_Black_Box

Theratechnologies Case Study – early company history In the Theratechnologies (TSX: TH) case study which I will cover in the next several blogs, I will ask four main questions. In order to get the background to answer the first question, the key source of information is the AIFs found at http://www.sedar.com. The oldest AIF from […]

read more


MondayDealTitle

Welcome to your Monday Biotech Deal Review for March 16th, 2015! *A day late, but here is the Monday Deal Review for March 16th. The big news this week was Valeant’s big win over Endo International for acquisition of Salix Pharmaceuticals.   Valeant raised the price for Salix by about a billion US dollars in a new […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for March 9th, 2015!   *A day late, but here is the Monday Deal Review for March 9th. This week, Valeant announced that its Canadian subsidiary VRX Escrow Corp. has launched an offering of the U.S. dollar equivalent of approximately $9.6 billion aggregate principal amount of senior unsecured notes […]

read more


Logo_DS-517x270RE3

I appreciate the chance to contribute to Brian and Jolyon’s forum. I have long admired their bold decision to fill a vacuum in Canadian healthcare investment banking at a time when the economic sentiment was anything but optimistic. Of course the pessimism of 2008 has evolved into exuberance over the past couple of years. How […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for March 6th, 2015! Nat Cell Biol. 2015 Mar; 17(3):217-27. Expansion of stem cells counteracts age-related mammary regression in compound Timp1/Timp3 null mice.   Proc Natl Acad Sci U S A. 2015 Feb 24; 112(8):E871-80. Dysregulation of Escherichia coli α-hemolysin expression alters the course of acute and persistent urinary tract […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for March 2nd, 2015!   This week, Centric Health Corporation announced that it completed the acquisition of 100% of Pharmacare Fulfillment Center Ltd, in a transaction valued at up to $34.0 million. In addition, TSO3 increased the size of its previously announced underwritten public offering from 8,000,000 units to […]

read more


Part4_Biotech_Black_Box

Information – some of the free sources    In most cases, you will be assessing a company, a product or a technology. The valuation of the stream of expenses and revenues for the development and commercialization of a product or a service is the simplest situation. If you are valuing a company, you are valuing […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for February 23rd, 2015!   This week’s post covers the last two weeks of activity due to last week’s family day holiday for parts of Canada. The last two weeks saw a lot of activity on the financing front, with Transition Therapeutics raising about $20 million in a public […]

read more